Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.

Breast cancer research and treatment - 1 Aug 2017

Maxwell Kara N, Soucier-Ernst Danielle, Tahirovic Emin, Troxel Andrea B, Clark Candace, Feldman Michael, Colameco Christopher, Kakrecha Bijal, Langer Melissa, Lieberman David, Morrissette Jennifer J D, Paul Matt R, Pan Tien-Chi, Yee Stephanie, Shih Natalie, Carpenter Erica, Chodosh Lewis A, DeMichele Angela

Abstract excerpt

PURPOSE: Breast cancer metastases differ biologically from primary disease; therefore, metastatic biopsies may assist in treatment decision making. Commercial genomic testing of both tumor and circulating tumor DNA have become available clinically, but utility of these tests in breast cancer management remains unclear. METHODS: Patients undergoing a clinically indicated metastatic tumor biopsy were consented to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to DNA, Neoplasm

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Neoplasm Metastasis

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 28500398
DOI: 10.1007/s10549-017-4257-x
PMCID: PMC5584374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.PMID 28500398Read ↗

Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.Semantic proximity Read ↗

Landscape of circulating tumour DNA in metastatic breast cancer.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer.Semantic proximity Read ↗

The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer.Semantic proximity Read ↗

Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.Semantic proximity Read ↗

Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.Semantic proximity Read ↗

Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer.Semantic proximity Read ↗

The dynamic range of circulating tumor DNA in metastatic breast cancer.Semantic proximity Read ↗

Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast CancerSemantic proximity Read ↗

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.Semantic proximity Read ↗

Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.Semantic proximity Read ↗

Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.